Drug Discovery Featured Articles & Applications

31. From Matrix To Medicine: New Frontiers In Treating Pulmonary Fibrosis And PH 6/25/2025

    Halo Biosciences is building a pipeline based on novel insights into how extracellular matrix dysregulation drives disease. We caught up with its leaders to discuss their approach to drug targeting and early development.

32. Tackling Antimicrobial Resistance With Precision Targeting 6/20/2025

    TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance. We caught up with the company's CEO and CSO to discuss their approach to early R&D.

33. Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet 6/19/2025

    This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making.

34. A Guide To Designing mRNA Medicines 6/10/2025

    A poorly designed mRNA sequence can create ongoing difficulties during downstream clinical development and manufacture. Let's take a closer look at strategies and design software that you can employ.

35. Bracing For The Impact Of The Federal Workforce Reduction 6/9/2025

    The federal workforce reductions pose significant challenges for the life sciences industry, particularly for R&D, supply chain oversight, and industry workforce development.

36. Radiopharmaceuticals: Navigating FDA Guidance And CMC Considerations 6/2/2025

    The unique nature of radiopharmaceuticals necessitates specialized regulatory considerations, particularly for chemistry, manufacturing, and controls (CMC).

37. Designing Our Way Toward Circular RNA Medicines With AI 5/21/2025

    The closed-loop structure of circular RNA can offer sustained, durable expression. We caught up with Sail Biomedicines' Kerry Benenato and Rajesh Ramaswamy to chat about ways to leverage AI for design/engineering.

38. Will Genome Modifications Define Next-Gen AAV Vectors? 5/20/2025

    AAV vectors composed of naturally occurring capsids are suboptimal. Gentle genetic alterations hold promise for safer, more efficient therapy.

39. Formulation Is Key For Y-mAbs' Self-Assembling Antibody 5/16/2025

    The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment.

40. ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy 5/12/2025

    Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.